Play Earnings CallPlay Earnings Call
GeneDx Holdings Corp. (WGS) Q1 2026 Earnings Call May 4, 2026 4:30 PM EDT
Company Participants
Sabrina Dunbar
Katherine Stueland – President, CEO & Director
Kevin Feeley – Chief Financial Officer
Conference Call Participants
Mark Massaro – BTIG, LLC, Research Division
David Westenberg – Piper Sandler & Co., Research Division
Daniel Brennan – TD Cowen, Research Division
William Bonello – Craig-Hallum Capital Group LLC, Research Division
Tycho Peterson – Jefferies LLC, Research Division
Keith Hinton
Kyle Mikson – Canaccord Genuity Corp., Research Division
Subhalaxmi Nambi – Guggenheim Securities, LLC, Research Division
Brandon Couillard – Wells Fargo Securities, LLC, Research Division
Presentation
Operator
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the GeneDx First Quarter 2026 Earnings Conference Call. [Operator Instructions] Please be reminded that this conference call is being recorded.
At this time, I’d like to introduce your host for today’s presentation, Ms. Sabrina Dunbar of Investor Relations. Ma’am, please begin.
Sabrina Dunbar
Thank you, operator, and thank you to everyone for joining us today. On the call, we have Katherine Stueland, President and Chief Executive Officer; and Kevin Feeley, Chief Financial Officer. Earlier today, GeneDx released financial results for the first quarter ended March 31, 2026.
Before we begin, please take note of our cautionary statement. We may make forward-looking statements on today’s call, including about our business plans, guidance and outlook. Forward-looking statements inherently involve risks and uncertainties and only reflect our view as of today, May 4, and we’re under no obligation to update. When discussing our results, we refer to non-GAAP measures, which exclude certain items from reported results. Please refer to our first quarter 2026 earnings release and slides available at ir.genedx.com for definitions and reconciliations of non-GAAP measures and additional information regarding our results, including a discussion of factors that could cause actual results to materially differ from forward-looking statements.
